Xenetic Biosciences Inc (NASDAQ:XBIO – Get Free Report) was the target of a significant drop in short interest during the month of May. As of May 15th, there was short interest totalling 3,900 shares, a drop of 43.5% from the April 30th total of 6,900 shares. Approximately 0.3% of the company’s shares are sold short. Based on an average trading volume of 7,800 shares, the short-interest ratio is currently 0.5 days.
Hedge Funds Weigh In On Xenetic Biosciences
A hedge fund recently bought a new stake in Xenetic Biosciences stock. LGT Group Foundation bought a new position in shares of Xenetic Biosciences Inc (NASDAQ:XBIO – Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 11,000 shares of the company’s stock, valued at approximately $41,000. LGT Group Foundation owned approximately 0.71% of Xenetic Biosciences as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 15.12% of the company’s stock.
Wall Street Analyst Weigh In
Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Xenetic Biosciences in a research report on Wednesday, April 9th.
Xenetic Biosciences Stock Down 2.3%
Shares of NASDAQ XBIO opened at $2.91 on Friday. Xenetic Biosciences has a 52-week low of $2.20 and a 52-week high of $5.20. The firm has a fifty day moving average of $2.76 and a 200-day moving average of $3.59. The stock has a market capitalization of $4.49 million, a PE ratio of -1.09 and a beta of 2.31.
Xenetic Biosciences (NASDAQ:XBIO – Get Free Report) last issued its earnings results on Tuesday, May 13th. The company reported ($0.59) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.13. Xenetic Biosciences had a negative return on equity of 49.51% and a negative net margin of 161.63%. The firm had revenue of $0.59 million for the quarter, compared to analysts’ expectations of $0.52 million. Equities research analysts expect that Xenetic Biosciences will post -1.01 EPS for the current fiscal year.
Xenetic Biosciences Company Profile
Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.
Further Reading
- Five stocks we like better than Xenetic Biosciences
- How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?
- Near 52-Week Lows, These 3 Mid-Cap Stocks Are Worth a Look
- Investing in Travel Stocks Benefits
- 3 Overlooked Dividend Plays for Income in Volatile Times
- What Investors Need to Know About Upcoming IPOs
- AXON: Competition Intensifies as Motorola Makes $4.4B Acquisition
Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.